For US residents only.

Monitoring Treatment

KISQALI + HORMONE THERAPY

Monitoring Treatment Monitoring Treatment

Monitoring Your Treatment

Your doctor may conduct certain tests before and during your treatment with KISQALI® (ribociclib) to determine if it's the right option for you. These tests may include:

 

icon-heart Heart Monitoring 

•  Electrocardiogram (ECG or EKG)
: An electrocardiogram, also known as an ECG or EKG, is a test that shows changes in the electrical activity of the heart over time

 

 

icon-blood-dropBlood Tests 

• Electrolytes Panel
: A blood test that measures the main electrolytes in the body—potassium, calcium, phosphorus, and magnesium—to check for an imbalance of the electrolytes or an acid–base imbalance
Complete Blood Count (CBC): A measure of the number of red blood cells, white blood cells, and platelets in the blood. A CBC also measures the amount of hemoglobin (substance in the blood that carries oxygen) and the hematocrit (the amount of whole blood that is made up of red blood cells)
Liver Function Test (LFT): A blood test to measure the blood levels of certain substances released by the liver. A high or low level of certain substances can be a sign of liver disease

 

 

At any time, your health care team may stop, decrease, or tell you to wait to begin your treatment with KISQALI. You should always take KISQALI exactly as your doctor tells you.

KISQALI Care @ Home Monitoring

KISQALI Care, our comprehensive patient support program, can provide you with a dedicated person who will be there to help schedule your required monitoring tests, including electrocardiograms (ECGs) and bloodwork, in the comfort of your own home through the KISQALI Care @ Home Monitoring program (for eligible patients).* For more information, call 1-800-282-7630 to speak with a KISQALI Care Patient Navigator.

 

*Limitations apply. KISQALI Care @ Home Monitoring is not available to patients with Medicare, Medicaid, or any other federal or state program, or residents of Michigan, Minnesota, or Rhode Island. Novartis reserves the right to terminate or modify this program at any time.